Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab - Takeaways - MDSpire

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

  • By

  • Jens Rathmann

  • Hiba Kadhem

  • Mårten Segelmark

  • David Jayne

  • Aladdin J. Mohammad

  • June 16, 2026

  • 0 min

Share

  • 1

    Hypogammaglobulinaemia (HG) occurred in 45% of rituximab-treated patients with ANCA-associated vasculitis in a Swedish cohort study.

  • 2

    The incidence rate of HG was 16.1 per 100 person-years, with a higher rate of 17.6 per 100 person-years when excluding preexisting cases.

  • 3

    A lower baseline IgG level was identified as an independent predictor of subsequent HG development in rituximab-treated patients.

  • 4

    Severe infections were reported in 35% of patients with HG, but HG was not associated with an increased risk of severe infections.

  • 5

    The median time to HG development after rituximab treatment was 3.5 months, highlighting the need for close IgG monitoring.

Original Source(s)

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

  • by Jens Rathmann, Hiba Kadhem, Mårten Segelmark, David Jayne, Aladdin J. Mohammad

  • June 16, 2026

Related Content

Serum complement system activation in normal healing and atrophic non-union of human long bone fractures

CURE: a phase-based therapeutic framework for chronic inflammation

Decoding autoimmune disease with single-cell immune repertoire and transcriptome sequencing: mechanisms and therapeutic opportunities